Quetiapine is an atypical antipsychotic that can stabilise mood from any index episode of bipolar disorder. This study investigated the effects of seven-day quetiapine administration on sleep, circadian rhythms and emotional processing in healthy volunteers.
Methods:
Twenty healthy volunteers received 150 mg quetiapine XL for seven nights and 20 matched controls received placebo. Sleep-wake actigraphy was completed for one week both pre-dose and during drug treatment. On Day 8, participants completed emotional processing tasks.
Results:
Actigraphy revealed that quetiapine treatment increased sleep duration and efficiency, delayed final wake time and had a tendency to reduce within-day variability. There were no effects of quetiapine on subjective ratings of mood or energy. Quetiapine-treated participants showed diminished bias towards positive words and away from negative words during recognition memory. Quetiapine did not significantly affect facial expression recognition, emotional word categorisation, emotion-potentiated startle or emotional word/faces dot-probe vigilance reaction times.
Conclusions:
These changes in sleep timing and circadian rhythmicity in healthy volunteers may be relevant to quetiapine’s therapeutic actions. Effects on emotional processing did not emulate the effects of antidepressants. The effects of quetiapine on sleep and circadian rhythms in patients with bipolar disorder merit further investigation to elucidate its mechanisms of action.
BandelowBChouinardGBobesJ. (2010) Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol13: 305–320.
4.
BauerMPretoriusHWConstantEL. (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry70: 540–549.
5.
BowdenCLGrunzeHMullenJ. (2005) A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry66: 111–121.
6.
CalabreseJRKeckPEMacfaddenW. (2005) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry162: 1351–1360.
7.
CohrsSRodenbeckAGuanZ. (2004) Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl)174: 421–429.
8.
CutlerAJMontgomerySAFeifelD. (2009) Extended release quetiapine fumarate monotherapy in major depressive disorder: A placebo- and duloxetine-controlled study. J Clin Psychiatry70: 526–539.
GiménezSClosSRomeroS. (2007) Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacology (Berl)190: 507–516.
11.
GrierJB (1971) Nonparametric indexes for sensitivity and bias: Computing formulas. Psychol Bull75: 424–429.
12.
HarmerCJde BodinatCDawsonGR. (2011a) Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. J Psychopharmacol25: 1159–1167.
13.
HarmerCJCowenPJGoodwinGM (2011b) Efficacy markers in depression. J Psychopharmacol25: 1148–1158.
14.
HarmerCJShelleyNCCowenPJ. (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry161: 1256–1263.
15.
HarveyAG (2008) Sleep and circadian rhythms in bipolar disorder: Seeking synchrony, harmony, and regulation. Am J Psychiatry165: 820–829.
16.
HarveyAGSchmidtDAScarnàA. (2005) Sleep-related functioning in euthymic patients with bipolar disorder, patients with insomnia, and subjects without sleep problems. Am J Psychiatry162: 50–57.
17.
HorneJOstbergO (1976) A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol4: 97–110.
18.
JonesSHHareDEvershedK (2005) Actigraphic assessment of circadian activity and sleep patterns in bipolar disorder. Bipolar Disord7: 176–186.
19.
LangPBradleyMCuthbertB (1998) International Affective Picture System (IAPS): Technical Manual and Affective Ratings. Gainesville, FL: University of Florida, Center for Research in Psychophysiology. http://www.csea.phhp.ufl.edu/Media.html
20.
LarsonCLRuffaloDNietertJY. (2000) Temporal stability of the emotion-modulated startle response. Psychophysiology37: 92–101.
21.
MatsumotoJEkmanP (1988) Japanese and Caucasian Facial Expression of Emotion (JACFEE) and Neutral Faces (JACNeuF). San Francisco: Human Interaction Laboratory.
22.
MehtaMAHintonECMontgomeryAJ. (2005) Sulpiride and mnemonic function: Effects of a dopamine D2 receptor antagonist on working memory, emotional memory and long-term memory in healthy volunteers. J Psychopharmacol19: 29–38.
23.
MillerDD (2004) Atypical antipsychotics: Sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry6: 3–7.
24.
MurphySEYiendJLesterKJ. (2009) Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol 12: 169–179.
25.
NasrallahHA (2008) Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles. Mol Psychiatry13: 27–35.
26.
NelsonHE (1982) National Adult Reading Test (NART): Test Manual. Windsor: NFER-Nelson,
27.
PiraLMongeauRPaniL (2004) The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat prefrontal cortex. Eur J Pharmacol504: 61–64.
28.
RockPLGoodwinGHarmerCJ. (2014) Daily rest-activity patterns in the bipolar phenotype: A controlled actigraphy study. Chronobiol Int31: 290–296.
29.
SheehanDJanavsJBakerR. (2005) M. I. N. I. Plus Mini International Neuropsychiatric Interview. 1–55.
TellegenAWatsonDClarkL (1988) Development and validation of brief measures of positive and negative affect: The PANAS scales. J Personal Soc54: 1063–1070.
32.
WeislerRJoyceJMMcGillL. (2009) Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. CNS Spectr14: 299–313.
33.
WeislerRHMontgomerySAEarleyWR. (2012) Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: A pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol27: 27–39.
34.
WuJCBunneyWE (1990) The biological basis of an antidepressant response to sleep deprivation and relapse: Review and hypothesis. Am J Psychiatry147:14–21.
35.
WulffKGattiSWettsteinJG. (2010) Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci11: 589–599.
36.
Von ZerssenDStrianFSchwarzD (1974) Evaluation of depressive states, especially in longitudinal studies. Mod Probl Pharmacopsychiatry7: 189–202.
